ARTICLE | Company News
Biovitrum, GlaxoSmithKline deal
October 28, 2002 8:00 AM UTC
GSK received exclusive rights to develop and market Biovitrum's 5-HT2C serotonin receptor agonist compounds, including BVT.933, an appetite suppressant in Phase II testing. Biovitrum retains rights in...